CardConnect Corp. Reports First Quarter 2017 Results
May 10, 2017 11:32 am UTC| Business
KING OF PRUSSIA, Pa., May 10, 2017 -- CardConnect Corp. (NASDAQ:CCN) (“CardConnect”), one of the nation's leading payment processors, today provided financial results for the first quarter ended March 31, 2017. Revenue...
CardConnect Corp. Reports First Quarter 2017 Results
May 10, 2017 11:32 am UTC| Business
KING OF PRUSSIA, Pa., May 10, 2017 -- CardConnect Corp. (NASDAQ:CCN) (“CardConnect”), one of the nation's leading payment processors, today provided financial results for the first quarter ended March 31, 2017. Revenue...
Adaptimmune Reports First Quarter 2017 Financial Results
May 10, 2017 11:32 am UTC| Business
– Offerings in March and April raised net proceeds of $103.2 million; operations funded through to late 2019– –Initiated study with wholly-owned AFP SPEAR T-cells– – Initial data from three wholly-owned assets (MAGE-A4,...
Adaptimmune Reports First Quarter 2017 Financial Results
May 10, 2017 11:32 am UTC| Business
– Offerings in March and April raised net proceeds of $103.2 million; operations funded through to late 2019– –Initiated study with wholly-owned AFP SPEAR T-cells– – Initial data from three wholly-owned assets (MAGE-A4,...
Adaptimmune Reports First Quarter 2017 Financial Results
May 10, 2017 11:32 am UTC| Business
– Offerings in March and April raised net proceeds of $103.2 million; operations funded through to late 2019– –Initiated study with wholly-owned AFP SPEAR T-cells– – Initial data from three wholly-owned assets (MAGE-A4,...
May 10, 2017 11:32 am UTC| Business
PHILADELPHIA and OXFORD, U.K., May 10, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its AFP SPEAR T-cell study...
May 10, 2017 11:32 am UTC| Business
PHILADELPHIA and OXFORD, U.K., May 10, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its AFP SPEAR T-cell study...